Akari Therapeutics, Plc (AKTX)
AKTX Price and Sentiment
AKTX Latest news
Akari Therapeutics Announces Presentation at Annual Complement-Based Drug Development Summit
2021-10-26 08:00NEW YORK and LONDON, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated, today announces that Professor Tim Higenbottam, Scientific & Clinical Advisor to Akari and President Faculty of the Pharmaceutical Medicine of the Royal Colleges of Physicians U.K., will present at the 5th Annual Complement-based Drug Development Summit 2021 being held virtually, October 26 – 28, 2021. Professor Higenbottam will be presenting during the timeslot, Understanding Complement Dysregulation in COVID-19 & Key Learnings for Managing Complement Inhibition in Long-COVID, and will address the role of complement dysregulation in a wide range of diseases, learnings from COVID-19, and the future role of complement plus LTB4 inhibition by nomacopan in treating these diseases in an acute setting.
Akari Therapeutics Announces New Data with Nomacopan from its Surface of the Eye Program
2021-10-25 08:30NEW YORK and LONDON, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated, today announces data highlighting the potential of nomacopan in the surface of the eye in Allergy, European Journal of Allergy and Clinical Immunology.
Akari Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Clinical Progress
2021-09-22 08:30NEW YORK and LONDON, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated, today announced its financial results for the second quarter of 2021, as well as recent clinical progress.
Akari Therapeutics to Present Its Phase III Plans for Nomacopan in Patients with Bullous Pemphigoid at the 2021 International Pemphigus & Pemphigoid Foundation (IPPF) Scientific Symposium
2021-09-10 08:30NEW YORK and LONDON, Sept. 10, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated, today announced that Miles Nunn, Ph.D., Chief Scientific Officer of Akari Therapeutics, and Sanjeev Khindri, M.D., Medical Director of Akari Therapeutics, will present a poster outlining the design of the Company's Phase III planned pivotal study of nomacopan in patients with moderate to severe bullous pemphigoid (BP) at the 2021 International Pemphigus & Pemphigoid Foundation (IPPF) Scientific Symposium.
Akari Therapeutics to Present at the H.C. Wainwright Global Investment Conference
2021-09-07 07:00NEW YORK and LONDON, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated, today announced that Clive Richardson, Chief Executive Officer, will present at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually September 13-15, 2021.
Akari Therapeutics Announces Private Placement
2021-07-07 09:15NEW YORK and LONDON, July 07, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX) (“Akari” or the “Company”), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are implicated, today announced that it has entered into definitive securities purchase agreements with certain accredited and institutional investors, led by existing investors of the Company, including Dr. Ray Prudo, the Company's Chairman, to receive gross proceeds of approximately $12 million through a private placement of its equity securities.
Akari Therapeutics Reports Q1 2021 Financial Results and Highlights Recent Clinical Progress
2021-06-29 16:01NEW YORK and LONDON, June 29, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated, today announced financial results for the first quarter of 2021, as well as recent clinical progress.
Akari Therapeutics' Nomacopan Secures Expediated Review Tag For Blistering Skin Disorder
2021-04-28 10:25The FDA has granted Fast Track designation to Akari Therapeutics Plc's (NASDAQ: AKTX) nomacopan to treat patients with moderate and severe Bullous Pemphigoid (BP). Nomacopan has also been granted orphan drug designation for nomacopan to treat BP by the FDA and the European Medicines Agency (EMA).
AKTX Stock: Over 20% Increase Pre-Market Explanation
2021-04-28 08:28The stock price of Akari Therapeutics PLC (NASDAQ: AKTX) increased by over 20% pre-market. This is why it happened.
Akari Therapeutics Announces Poster Presentation of Phase II Bullous Pemphigoid Disease and Phase III Trial Design at American Academy of Dermatology Association Virtual Meeting Experience
2021-04-22 07:30NEW YORK and LONDON, April 22, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and leukotriene systems are implicated, announced today that it will present a poster at the American Academy of Dermatology Association (AAD) Virtual Meeting Experience (VMX) taking place April 23-25, 2021.